New drugs for the treatment of complicated intra-abdominal infections in the era of increasing antimicrobial resistance

Ling-Shan Syue, Yen Hsu Chen, Wen-Chien Ko, Po Ren Hsueh

研究成果: Short survey

24 引文 斯高帕斯(Scopus)

摘要

The continuing increase in multidrug-resistant organisms (MDROs) worldwide has created new challenges in treating complicated intra-abdominal infections (cIAIs). A number of novel antimicrobial agents have been developed against resistant pathogens. To target extended-spectrum β-lactamase (ESBL)-producing pathogens, novel β-lactam antibiotics, such as ceftolozane/tazobactam, ceftazidime/avibactam, aztreonam/avibactam, imipenem/relebactam and S-649266, are antimicrobial alternatives for cIAIs. Two new drugs, eravacycline and plazomicin, have activity against Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae, carbapenem-resistant Acinetobacter baumannii and ESBL-producers. New lipoglycopeptides and oxazolidinones provide feasible options against resistant Gram-positive pathogens. These novel antimicrobials may play a role in improving the clinical outcomes of cIAIs caused by MDROs.

原文English
頁(從 - 到)250-258
頁數9
期刊International journal of antimicrobial agents
47
發行號4
DOIs
出版狀態Published - 2016 四月 1

All Science Journal Classification (ASJC) codes

  • Microbiology (medical)
  • Infectious Diseases
  • Pharmacology (medical)

指紋 深入研究「New drugs for the treatment of complicated intra-abdominal infections in the era of increasing antimicrobial resistance」主題。共同形成了獨特的指紋。

  • 引用此